TRAPPC6A

Summary

TRAPPC6A (trafficking protein particle complex subunit 6A, HGNC:23069) is a protein-coding gene on chromosome 19q13.32, encoding Trafficking protein particle complex subunit 6A (O75865). May play a role in vesicular transport during the biogenesis of melanosomes.

This gene encodes a component of the trafficking protein particle complex, which tethers transport vesicles to the cis-Golgi membrane. Loss of expression of the related gene in mouse affects coat and eye pigmentation, suggesting that the encoded protein may be involved in melanosome biogenesis. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 79090 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_001270891

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23069
Approved symbol	TRAPPC6A
Name	trafficking protein particle complex subunit 6A
Location	19q13.32
Locus type	gene with protein product
Status	Approved
Aliases	TRS33, MGC2650, HSPC289
Ensembl gene	ENSG00000007255
Ensembl biotype	protein_coding
OMIM	610396
Entrez	79090

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 retained_intron

ENST00000006275, ENST00000585934, ENST00000587818, ENST00000588062, ENST00000592647, ENST00000879979, ENST00000940426, ENST00000940427, ENST00000940428

RefSeq mRNA: 4 — MANE Select: NM_001270891 NM_001270891, NM_001270892, NM_001270893, NM_024108

CCDS: CCDS12655, CCDS59395, CCDS59396, CCDS59397

Canonical transcript exons

ENST00000585934 — 6 exons

Exon	Start	End
ENSE00002865685	45178135	45178237
ENSE00002900972	45162933	45163223
ENSE00003491197	45164853	45164970
ENSE00003500714	45165127	45165194
ENSE00003512065	45164164	45164247
ENSE00003666601	45163916	45164009

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 95.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.9957 / max 125.1835, expressed in 1667 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181445	5.4785	1574
181444	1.5173	763

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	95.20	gold quality
granulocyte	CL:0000094	94.13	gold quality
skin of abdomen	UBERON:0001416	93.86	gold quality
endometrium epithelium	UBERON:0004811	93.44	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	93.36	gold quality
skin of leg	UBERON:0001511	93.27	gold quality
right lobe of liver	UBERON:0001114	93.21	gold quality
mucosa of transverse colon	UBERON:0004991	93.16	gold quality
metanephros cortex	UBERON:0010533	92.31	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.23	gold quality
zone of skin	UBERON:0000014	91.98	gold quality
left lobe of thyroid gland	UBERON:0001120	91.85	gold quality
spleen	UBERON:0002106	91.65	gold quality
right lobe of thyroid gland	UBERON:0001119	91.58	gold quality
spinal cord	UBERON:0002240	91.54	gold quality
monocyte	CL:0000576	91.24	gold quality
leukocyte	CL:0000738	91.21	gold quality
mononuclear cell	CL:0000842	91.14	gold quality
thyroid gland	UBERON:0002046	91.07	gold quality
transverse colon	UBERON:0001157	90.97	gold quality
adult mammalian kidney	UBERON:0000082	90.96	gold quality
apex of heart	UBERON:0002098	90.55	gold quality
body of stomach	UBERON:0001161	90.51	gold quality
left adrenal gland cortex	UBERON:0035825	90.18	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.12	gold quality
right adrenal gland	UBERON:0001233	90.01	gold quality
right adrenal gland cortex	UBERON:0035827	89.92	gold quality
left adrenal gland	UBERON:0001234	89.81	gold quality
putamen	UBERON:0001874	89.73	gold quality
mucosa of stomach	UBERON:0001199	89.35	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.35
E-MTAB-7606	no	1246.56

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF

miRNA regulators (miRDB)

8 targeting TRAPPC6A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-4324	99.04	70.14	1569
HSA-MIR-7973	96.48	65.54	502
HSA-MIR-6846-3P	94.80	65.19	389

Literature-anchored findings (GeneRIF, showing 3)

• Mapping and characterization of mouse Trappc6a, along with a description of the human homolog. (PMID:16697553)
• Host cellular protein TRAPPC6ADelta interacts with influenza A virus M2 protein and regulates viral propagation by modulating M2 trafficking. (PMID:27795429)
• Missense mutation in TRAPPC6A identified in patients with a neurodevelopmental syndrome, affects stability of the TRAPP complex. (PMID:29391579)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	trappc6bl	ENSDARG00000033171
mus_musculus	Trappc6a	ENSMUSG00000002043
rattus_norvegicus	Trappc6a	ENSRNOG00000017468
drosophila_melanogaster	Trs33	FBGN0266722
caenorhabditis_elegans		WBGENE00010699

Paralogs (1): TRAPPC6B (ENSG00000182400)

Protein

Protein identifiers

Trafficking protein particle complex subunit 6A — O75865 (reviewed: O75865)

All UniProt accessions (2): O75865, B7TZ90

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in vesicular transport during the biogenesis of melanosomes.

Subunit / interactions. Part of the multisubunit transport protein particle (TRAPP) complex. Heterodimer with TRAPPC3. The heterodimer TRAPPC3-TRAPPC6A interacts with TRAPPC2L. Interacts with TRAPPC2L.

Subcellular location. Golgi apparatus. cis-Golgi network. Endoplasmic reticulum.

Similarity. Belongs to the TRAPP small subunits family. BET3 subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
O75865-1	1	yes
O75865-2	2
O75865-3	3
O75865-4	4

RefSeq proteins (4): NP_001257820, NP_001257821, NP_001257822, NP_077013 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007194	TRAPP_component	Family
IPR024096	NO_sig/Golgi_transp_ligand-bd	Homologous_superfamily
IPR037992	TRAPPC6/Trs33	Family

Pfam: PF04051

UniProt features (21 total): helix 10, strand 4, splice variant 3, chain 1, modified residue 1, turn 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2C0J	X-RAY DIFFRACTION	2.2
2J3T	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75865-F1	90.51	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 33

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-204005	COPII-mediated vesicle transport
R-HSA-8876198	RAB GEFs exchange GTP for GDP on RABs

MSigDB gene sets: 150 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, JI_RESPONSE_TO_FSH_UP, GOBP_VESICLE_LOCALIZATION, GOBP_VESICLE_ORGANIZATION, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_VESICLE_TARGETING, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, MODULE_16, BROWNE_HCMV_INFECTION_48HR_DN, GOCC_TRANS_GOLGI_NETWORK, GOBP_ENDOPLASMIC_RETICULUM_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT, DELYS_THYROID_CANCER_DN, MODULE_88, BASAKI_YBX1_TARGETS_DN

GO Biological Process (6): endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), COPII vesicle coat assembly (GO:0048208), obsolete vesicle tethering (GO:0099022), vesicle-mediated transport (GO:0016192), regulation of GTPase activity (GO:0043087), Golgi vesicle transport (GO:0048193)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), cis-Golgi network (GO:0005801), trans-Golgi network (GO:0005802), cytosol (GO:0005829), TRAPP complex (GO:0030008), TRAPPIII protein complex (GO:1990072), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
ER to Golgi Anterograde Transport	1
Rab regulation of trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
intracellular membrane-bounded organelle	3
cellular anatomical structure	2
endomembrane system	2
Golgi apparatus	2
intercellular transport	1
intracellular transport	1
Golgi vesicle transport	1
vesicle coat assembly	1
protein-containing complex assembly	1
COPII-coated vesicle budding	1
transport	1
cellular process	1
GTPase activity	1
regulation of hydrolase activity	1
vesicle-mediated transport	1
binding	1
intracellular anatomical structure	1
Golgi apparatus subcompartment	1
vesicle tethering complex	1
intracellular protein-containing complex	1
TRAPP complex	1

Protein interactions and networks

STRING

768 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRAPPC6A	TRAPPC5	Q8IUR0	998
TRAPPC6A	TRAPPC4	Q9Y296	998
TRAPPC6A	TRAPPC1	Q9Y5R8	998
TRAPPC6A	TRAPPC2	P0DI81	997
TRAPPC6A	TRAPPC3	O43617	996
TRAPPC6A	TRAPPC8	Q9Y2L5	966
TRAPPC6A	TRAPPC9	Q96Q05	898
TRAPPC6A	TRAPPC10	P48553	882
TRAPPC6A	TRAPPC12	Q8WVT3	727
TRAPPC6A	TRAPPC2L	Q9UL33	725
TRAPPC6A	TRAPPC11	Q7Z392	710
TRAPPC6A	RAB1A	P11476	706
TRAPPC6A	TRAPPC13	A5PLN9	680
TRAPPC6A	MYO18A	O95411	579
TRAPPC6A	USO1	O60763	545

IntAct

45 interactions, top by confidence:

A	B	Type	Score
TRAPPC6A	TRAPPC3	psi-mi:“MI:0915”(physical association)	0.850
TRAPPC3	TRAPPC6A	psi-mi:“MI:0915”(physical association)	0.850
TRAPPC6A	TRAPPC3	psi-mi:“MI:0914”(association)	0.850
RAB3IP	TRAPPC3	psi-mi:“MI:0914”(association)	0.700
RAB3IP	TRAPPC6A	psi-mi:“MI:0915”(physical association)	0.670
TRAPPC6A	Hoxa1	psi-mi:“MI:0915”(physical association)	0.570
Hoxa1	TRAPPC6A	psi-mi:“MI:0915”(physical association)	0.570
TRAPPC6A	ZMIZ2	psi-mi:“MI:0915”(physical association)	0.560
IKZF3	TRAPPC6A	psi-mi:“MI:0915”(physical association)	0.560
TRAPPC6A	HEL-S-101	psi-mi:“MI:0915”(physical association)	0.560
ZMIZ2	TRAPPC6A	psi-mi:“MI:0915”(physical association)	0.560
TRAPPC6A	IKZF3	psi-mi:“MI:0915”(physical association)	0.560
TRAPPC2L	TRAPPC13	psi-mi:“MI:0914”(association)	0.560
TRAPPC6A	Trappc3	psi-mi:“MI:0915”(physical association)	0.540
TRAPPC6A	Trappc3	psi-mi:“MI:0407”(direct interaction)	0.540

BioGRID (82): TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), ZMIZ2 (Two-hybrid), RAB3IP (Two-hybrid), TRAPPC6A (Affinity Capture-MS), TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), TRAPPC6A (Two-hybrid), TRAPPC6A (PCA), Hoxa1 (Affinity Capture-Western), TRAPPC6A (Affinity Capture-MS), TRAPPC6A (Affinity Capture-MS)

ESM2 similar proteins: B4S3A5, F1QMV3, O01757, O08700, O75865, P06814, P08096, P15847, P30182, P34605, P36149, P41810, P87078, P87303, P97390, Q01879, Q09191, Q09805, Q22307, Q24179, Q2M197, Q32L78, Q3T086, Q54GE3, Q54YG5, Q5F3Z1, Q61IU9, Q6AX60, Q6BIJ0, Q6BZX4, Q6GME1, Q6PEI7, Q7KQM2, Q86K94, Q86SZ2, Q94KJ7, Q9BMM1, Q9BMX3, Q9D289, Q9EQP2

Diamond homologs: F1QMV3, O75865, Q09784, Q32L78, Q3T086, Q78XR0, Q86SZ2, Q99394, Q9D289

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TRAPPC6A	“form complex”	“TRAPP III complex, TRAPPC2 variant”	binding
TRAPPC6A	“form complex”	“TRAPP III complex, TRAPPC2B variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 21 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RAB GEFs exchange GTP for GDP on RABs	7	79.0×	6e-12

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle tethering	6	396.5×	1e-13
COPII vesicle coat assembly	5	234.1×	2e-10
endoplasmic reticulum to Golgi vesicle-mediated transport	6	54.4×	1e-08

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	7
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1186 predictions. Top by Δscore:

Variant	Effect	Δscore
19:45163914:A:AC	donor_gain	1.0000
19:45163915:C:CC	donor_gain	1.0000
19:45163915:CAGA:C	donor_gain	1.0000
19:45164158:CCATA:C	donor_loss	1.0000
19:45164159:CATA:C	donor_loss	1.0000
19:45164160:ATACC:A	donor_loss	1.0000
19:45164161:TAC:T	donor_loss	1.0000
19:45164174:T:TA	donor_gain	1.0000
19:45164245:CCC:C	acceptor_gain	1.0000
19:45164246:CC:C	acceptor_gain	1.0000
19:45164246:CCC:C	acceptor_gain	1.0000
19:45164247:CC:C	acceptor_gain	1.0000
19:45164248:C:CC	acceptor_gain	1.0000
19:45164249:T:G	acceptor_loss	1.0000
19:45164847:TCCCA:T	donor_loss	1.0000
19:45164848:CCCAC:C	donor_loss	1.0000
19:45164849:CCAC:C	donor_loss	1.0000
19:45164850:CACCT:C	donor_loss	1.0000
19:45164005:AGGAA:A	acceptor_gain	0.9900
19:45164006:GGAA:G	acceptor_gain	0.9900
19:45164007:GAA:G	acceptor_gain	0.9900
19:45164008:AACTG:A	acceptor_loss	0.9900
19:45164009:AC:A	acceptor_loss	0.9900
19:45164010:C:CA	acceptor_loss	0.9900
19:45164010:C:CC	acceptor_gain	0.9900
19:45164011:T:A	acceptor_loss	0.9900
19:45164243:GTCCC:G	acceptor_gain	0.9900
19:45164244:TCCC:T	acceptor_gain	0.9900
19:45164245:CCCC:C	acceptor_gain	0.9900
19:45164248:C:T	acceptor_gain	0.9900

AlphaMissense

1031 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:45164889:G:C	F78L	0.962
19:45164889:G:T	F78L	0.962
19:45164891:A:G	F78L	0.962
19:45163216:G:C	F152L	0.957
19:45163216:G:T	F152L	0.957
19:45163218:A:G	F152L	0.957
19:45165145:C:T	G45D	0.948
19:45165158:C:G	G41R	0.948
19:45165158:C:T	G41R	0.948
19:45165158:C:A	G41W	0.946
19:45163978:C:T	G129D	0.940
19:45163217:A:G	F152S	0.939
19:45164903:A:G	W74R	0.936
19:45164903:A:T	W74R	0.936
19:45165157:C:T	G41E	0.931
19:45163945:A:T	V140D	0.922
19:45164241:A:C	Y93D	0.913
19:45164919:G:C	F68L	0.909
19:45164919:G:T	F68L	0.909
19:45164921:A:G	F68L	0.909
19:45163979:C:G	G129R	0.906
19:45164229:C:G	D97H	0.906
19:45164922:C:A	K67N	0.903
19:45164922:C:G	K67N	0.903
19:45163990:C:T	G125D	0.902
19:45163950:G:C	S138R	0.900
19:45163950:G:T	S138R	0.900
19:45163952:T:G	S138R	0.900
19:45164234:A:G	L95P	0.896
19:45164007:G:C	F119L	0.894

dbSNP variants (sampled 300 via entrez): RS1000026742 (19:45176420 C>A,T), RS1000246675 (19:45169755 C>G), RS1000673141 (19:45166619 C>T), RS1000749091 (19:45164952 C>T), RS1000783180 (19:45162439 C>A), RS1000832464 (19:45170899 C>T), RS1000897317 (19:45169451 T>A), RS1000978718 (19:45177271 G>A), RS1000988871 (19:45169183 C>T), RS1001011526 (19:45177547 T>C), RS1001013859 (19:45175348 A>C), RS1001213936 (19:45162589 C>G), RS1001277038 (19:45169267 G>A), RS1001284484 (19:45164735 G>A,T), RS1001470167 (19:45174846 C>A,T)

Disease associations

OMIM: gene MIM:610396 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (2): neurodevelopmental disorder (MONDO:0700092), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST000337_21	Quantitative traits	2.000000e-06
GCST000337_22	Quantitative traits	4.000000e-07
GCST004069_16	Cerebrospinal fluid AB1-42 levels	6.000000e-10
GCST007827_13	Alzheimer’s disease or HDL levels (pleiotropy)	7.000000e-22
GCST007827_3	Alzheimer’s disease or HDL levels (pleiotropy)	1.000000e-97
GCST007827_8	Alzheimer’s disease or HDL levels (pleiotropy)	3.000000e-36
GCST009496_21	Alzheimer’s disease (onset between ages 58 and 79)	8.000000e-09
GCST011351_22	Aspartate aminotransferase levels	1.000000e-10
GCST011352_12	Alanine aminotransferase levels	2.000000e-42

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	3
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	3
bisphenol A	increases expression, affects cotreatment	2
mercuric bromide	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Rotenone	decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
afuresertib	increases expression	1
dicrotophos	decreases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, increases expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	decreases methylation	1
cyfluthrin	decreases expression, decreases reaction	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Aspirin	increases expression	1

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism